People with cancer often face a tough choice when their disease spreads to just a few places. This situation is called oligometastatic cancer. A new study from British Columbia looked at a treatment called SABR, which uses focused radiation to hit tumors precisely. The team followed 380 patients who were at least 18 years old and had a life expectancy of at least six months. These patients had one to five spots of cancer that were either new or could not be controlled by previous therapy. Some even had cancer that became oligometastatic after treatment. The goal was to see if this approach could help them live longer and keep their cancer from growing back.
After an average follow-up of over four and a half years, the results showed promise. The median overall survival was 64.6 months. This means half the patients lived longer than that time. By the five-year mark, 58.6 percent of the group were still alive. Progression-free survival was 14.6 months on average, while 85.1 percent of patients maintained local control of their tumors for five years. The study did not report specific side effects or discontinuations, suggesting the treatment was well tolerated for this group.
The researchers note this was a single-arm trial without a direct comparison group. This design means we cannot say for sure that SABR caused these outcomes compared to other options. However, the favorable survival data may suggest a role for SABR beyond just the strict definition of oligometastatic disease. It highlights the potential benefit of durable local tumor control for patients with limited spread. This finding could change how doctors think about treating cancer that has spread to a few spots.
